Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
herpes
Biotech
Gilead pays $100M for first dibs on all Assembly Bio assets
Rather than buy the viral disease biotech, Gilead is paying $100 million upfront for opt-in rights on all Assembly’s current and future programs.
Nick Paul Taylor
Oct 17, 2023 7:00am
AiCuris sharpens strategic focus of infectious disease pipeline
Jul 6, 2023 11:12am
BioNTech lines up 5 infectious disease trials for 2023
Nov 7, 2022 6:57am
New antiviral class could halt treatment-resistant viruses
May 16, 2022 3:10pm
'Big data' analysis links herpes virus to Alzheimer's
Jun 21, 2018 1:21pm
More bad news for Vical as it abandons herpes vaccine
Jun 11, 2018 9:33am
